0NM7 Stock Overview
Manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0NM7 from our risk checks.
Virbac SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €349.00 |
| 52 Week High | €376.50 |
| 52 Week Low | €242.00 |
| Beta | 0.94 |
| 11 Month Change | -0.43% |
| 3 Month Change | -2.77% |
| 1 Year Change | 39.63% |
| 33 Year Change | 9.23% |
| 5 Year Change | 107.24% |
| Change since IPO | 549.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0NM7 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 4.3% | -1.6% | 0.8% |
| 1Y | 39.6% | 15.9% | 10.8% |
Return vs Industry: 0NM7 exceeded the UK Pharmaceuticals industry which returned 15.9% over the past year.
Return vs Market: 0NM7 exceeded the UK Market which returned 10.8% over the past year.
Price Volatility
| 0NM7 volatility | |
|---|---|
| 0NM7 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0NM7 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0NM7's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 5,459 | Sebastien Huron | corporate.virbac.com |
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners.
Virbac SA Fundamentals Summary
| 0NM7 fundamental statistics | |
|---|---|
| Market cap | €2.95b |
| Earnings (TTM) | €121.30m |
| Revenue (TTM) | €1.25b |
24.3x
P/E Ratio2.4x
P/S RatioIs 0NM7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0NM7 income statement (TTM) | |
|---|---|
| Revenue | €1.25b |
| Cost of Revenue | €433.87m |
| Gross Profit | €813.03m |
| Other Expenses | €691.73m |
| Earnings | €121.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 13, 2024
| Earnings per share (EPS) | 14.49 |
| Gross Margin | 65.20% |
| Net Profit Margin | 9.73% |
| Debt/Equity Ratio | 9.6% |
How did 0NM7 perform over the long term?
See historical performance and comparison